The present invention provides means and methods for diagnosing or treating B-cell malignancies. Novel conjugates for reverse targeting of B-cell receptors on malignant B cells are provided. The conjugates comprise a BCR antigen and a diagnostic or therapeutic agent. Also provided herein is a method for identifying patients disposed to respond favorably to treatment with a BCR antigen conjugate of the invention.
